Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 vs Guselkumab in Moderately to Severely Active Crohn's Disease
NCT07577843Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of guselkumab + golimumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
guselkumab + golimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07577843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577843.